Connecticut legislation · 2025 General Assembly
Connecticut HB6771: AN ACT ESTABLISHING AN ALZHEIMER'S DISEASE AND DEMENTIA TASK FORCE, REQUIRING HEALTH INSURANCE COVERAGE FOR BIOMARKER TESTING AN
Status: Chaptered, June 3, 2025
AN ACT ESTABLISHING AN ALZHEIMER'S DISEASE AND DEMENTIA TASK FORCE, REQUIRING HEALTH INSURANCE COVERAGE FOR BIOMARKER TESTING AND CONCERNING TRANSFERS AND DISCHARGES IN RESIDENTIAL CARE HOMES, TUITION WAIVERS FOR NURSING HOME RESIDENTS WHO TAKE COURSES AT REGIONAL COMMUNITY-TECHNICAL COLLEGES AND CLOSURES AND EVACUATIONS OF RESIDENTIAL CARE HOMES AND NURSING HOMES.
What the bill says
An act requiring health insurance coverage for biomarker testing. assembly convened.
From the introduced text:
AN ACT REQUIRING HEALTH INSURANCE COVERAGE FOR BIOMARKER TESTING. Assembly convened: Section 1. (NEW) (Effective January 1, 2026) (a) As used in this section: (1) "Biomarker" means a characteristic, including, but not limited to, a gene mutation or protein expression that can be objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a specific therapeutic intervention for a disease or condition. (2) "Biomarker testing" means the analysis of a patient's tissue, blood or other biospecimen for the presence of a biomarker, including, but not limited to, tests for a single substance, tests for multiple substances, diseases or conditions and whole genome sequencing. (b) Each individual health insurance policy providing coverage of the type specified in subdivisions (1), (2), (4), (11) and (12) of section 38a-469 of the general statutes delivered, issued for delivery, renewed, amended or continued in this state on or after January 1, 2026, shall provide LCO No. 3669 1 of Raised Bill No. 6771 coverage for biomarker testing for the purpose of diagnosis, treatment, appropriate management or ongoing monitoring of an insured's disease or condition. Sec. 2. (NEW) (Effective January 1, 2026) (a) As used in this section: (1) "Biomarker" means a characteristic, including, but not limited to, a gene mutation or protein expression that can be objectively measured …
Sponsors
- Mitch Bolinsky (R, 106) · primary sponsor
- Amy Morrin Bello (D, 28)
- Jane Garibay (D, 60)
- Saud Anwar (D, 3)
- Kevin Brown (D, 56)
- Anne Hughes (D, 135)
- William Heffernan (D, 115)
- Travis Simms (D, 140)
- Laurie Sweet (D, 91)
- Joshua Hall (D, 7)
- Hector Arzeno (D, 151)
- Lucia Dathan (D, 142)
Latest actions
- : Signed by the Governor
- : Transmitted to the Secretary of State
- : Transmitted by Secretary of the State to Governor
- : Public Act 25-16
- : Senate Adopted House Amendment Schedule A
- : Senate Passed as Amended by House Amendment Schedule A
- : In Concurrence
- : Favorable Report, Tabled for the Calendar, Senate
- : Senate Calendar Number 454
- : File Number 903
Votes
- Senate Roll Call 209 (May 21, 2026): 36 yea, 0 nay, passed
- House Roll Call 79 (May 8, 2026): 147 yea, 0 nay, passed
- Senate Roll Call 209 (May 21, 2025): 36 yea, 0 nay, passed
- House Roll Call 79 (May 8, 2025): 147 yea, 0 nay, passed
Common questions
- What is HB6771?
- HB6771 is a bill in the Connecticut Legislature (2025 General Assembly): AN ACT ESTABLISHING AN ALZHEIMER'S DISEASE AND DEMENTIA TASK FORCE, REQUIRING HEALTH INSURANCE COVERAGE FOR BIOMARKER TESTING AN.
- What does HB6771 do?
- In its own words: An act requiring health insurance coverage for biomarker testing. assembly convened.
- What is the status of HB6771?
- Chaptered as of June 3, 2025. Latest action: Signed by the Governor (June 3, 2025).
- Who sponsored HB6771?
- Mitch Bolinsky (R, 106), with 11 co-sponsors.
- Where is the official record for HB6771?
- On the Connecticut Legislature website: https://www.cga.ct.gov/asp/cgabillstatus/cgabillstatus.asp?selBillType=Bill&bill_num=HB06771&which_year=2025
Source: official Connecticut record. Tracked by Delilah, AI for legislation across all 50 states and Congress.